Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY: DGX )

138.30 -1.93 (-1.38%)
Official Closing Price Updated: 7:00 PM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 734,398
Open 139.78
Bid (Size) 137.70 (1)
Ask (Size) 138.90 (1)
Prev. Close 140.23
Today's Range 137.65 - 140.17
52wk Range 119.59 - 145.62
Shares Outstanding 122,180,759
Dividend Yield 2.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including 
Via MarketBeat
Peering Into Quest Diagnostics's Recent Short Interest
Via Benzinga

Performance

YTD
-1.79%
-1.79%
1 Month
-0.44%
-0.44%
3 Month
+6.98%
+6.98%
6 Month
+1.13%
+1.13%
1 Year
-2.19%
-2.19%

More News

Read More
Analyst Scoreboard: 7 Ratings For Quest Diagnostics
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High
Via Benzinga
Topics Cannabis
Exposures Cannabis
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Peering Into Quest Diagnostics's Recent Short Interest
Via Benzinga
The Analyst Landscape: 5 Takes On Quest Diagnostics
Via Benzinga
Balancing Dividends and Fundamentals: The Case of NYSE:DGX.
Via Chartmill
Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX
Via AB Newswire
Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
Via Talk Markets
Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic
Via Benzinga
DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
US Stocks Set To Open Fresh Week Higher On Big Tech Earnings Hopes: Analyst Warns Any Letdown Could Push Market 'Deeper Into Oversold Territory'
Via Benzinga
Key Takeaways From Quest Diagnostics Analyst Ratings
Via Benzinga
Why NYSE:DGX provides a good dividend, while having solid fundamentals.
Via Chartmill
Earnings Scheduled For April 23, 2024
Via Benzinga
(DGX) - Analyzing Quest Diagnostics's Short Interest
Via Benzinga
Why NYSE:DGX provides a good dividend, while having solid fundamentals.
Via Chartmill
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
LifeMD Shares Come Back to Life on GLP-1 Business Growth
Via MarketBeat
AMC Entertainment Tops The List Of High-Yielding Corporate Bonds — A Look At Yields As Bond Appetites Grow
Via Benzinga
Topics Bonds
Exposures Debt Markets
Breaking Down Quest Diagnostics: 7 Analysts Share Their Views
Via Benzinga
Spotify To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Is NYSE:DGX suited for dividend investing?
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.